Influencing policy (training slides from Fast Track Impact)
The efficiency of extracts of plants that have
1. EFFICIENCY OF PLANTS EXTRACTS
THAT CONTAIN MELATONIN IN
PARKINSON DISEASE RATS
Carlos J. Santos Pérez, RISE Student
2. Background Information
The rats have a very
similar neurological system
to human.
The cause of Parkinson
Disease in a patient is the
absence of dopamine.
Symptoms:
Trembling of the
extremities
Stiffness
Slowness
Poor balance or
coordination
3. Melatonin
Is an hormone that is produce in the brain by the
pineal gland, from the amino acid tryptophan.
Synthesis and release of melatonin are stimulated
by darkness and suppressed by light, suggesting
the involvement of melatonin in circadian rhythm
and regulation of diverse body functions.
Levels of melatonin in the blood are highest prior
to bedtime.
4. Melatonin Extract: Achillea millefolium
Achillea millefolium- a
plant that is commonly
called Achillea, we
can found it in North
America and it
contains a high
concentration of
melatonin
45.4 ng/g of the
plant.
5. Melatonin & Alzheimer
Recent studies indicate that the presence of
melatonin in Alzheimer improve patient
health, so we can investigate if melatonin
has the same effect in patients with other
neurodegenerative disease , in this case
Parkinson’s Disease.
6. Objectives
The objectives of this investigation are:
Determine if the extract of Achillea help patience with
Parkinson Disease to control their involuntarily
movements.
Prove that melatonin is a diverse remedial hormone that can
be use to treat Parkinson Disease Symptoms including the
lack of sleeping symptom
7. Hypothesis
If we apply melatonin extract of Achillea plant in
rats with Parkinson Disease then we should see less
involuntarily movement in the rats at higher
concentrations of extract.
8. Rotenone
The Rotenone Molecule is a
mithocondrial inhibitor that
have been used to induce
dopaminergic neuronal death.
Inhibit the pathway of
dopamine production.
That’s why it cause Parkinson’s
Disease.
Rotenone at 3 mg/kg/day
will induce degeneration of
the nigrostriatal dopaminergic
pathway (Caboni, 2004)
This will be subcutaneously
9. Procedure
Extracts of Achillea millefolium.
Need a Population of mice for the experiment.
Groups:
Control- It consist of 25 healthy rats and 25 sick rats. They
will not be affected by the extracts of Achillea millefolium.
Experimental- It consist of three group:
Concentration of 60%, will be injected subcutaneously.(25 rats)
Concentration of 10% , will be injected subcutaneously(25 rats)
10. Rats
Control Group Experimental
Group
Rats with
Rats with Parkinson’s- 40% Rats with Parkinson’s
Healthy Rat(No Parkinon’s concentration of 10% of ML(5mL
ML) Disease(No Ml) ML(5mL subcutaneously)
subcutaneously)
Alcohol(25) Levodopa(25)
11. How to do the extracts?
Tincture- Alcoholic extract that alcohol is the solvent.
We will use: 40% and 90% of alcohol and plant.
The ethanol extract have to be placed in rotatory
evaporator to eliminate the solvent, obtaining an
extract, which was weighed and stored in
dissecator.
12. Variables
Time of Dosis of both of the concentrations: daily
5ml/day This will be for at least 1 year.
Independent Variables- Concentrations and dosis of
the extracts may vary.
Dependent Variable- the temblors and involuntary
movements of the rats.
Type of Data- Qualitative. This research is based
on the observation of the rats behaviors.
13. Goals
If my hypothesis is reaffirmed I will proceed to use
different plants to do the extracts and compare
results.
As a second phase for my research project I will
expand my research work to primates.
14. References
Ferri, Fred F. Practical guide to the care of the medical patient. – 7th ed.
Pages: 776-777
Marsden CD. Problems with long-term levodopa therapy for Parkinson's
disease. Clin Neuropharmacol. 1994;Page 17
Marioni F. A straightforward procedure to biosynthesise melatonin using
freshly chopped Achillea millefolium L. as reagent Phytochemistry
Letters, Volume 1, Issue 2, 21 August 2008, Pages 107-110
German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain
dopaminergic cell loss in Parkinson's disease: Computer visualization. Ann
Neurol. 1989; 26:507–514.
http://www.ncbi.nlm.nih.gov/pubmed/18289173 Last visit- 7/25/2010
http://www.ncbi.nlm.nih.gov/pubmed/18289173 Last visit- 7/25/2010
http://www.ncbi.nlm.nih.gov/pubmed/15540952 Last visit- 7/25/2010
http://www.ncbi.nlm.nih.gov/pubmed/15540952 Last visit- 7/25/2010